Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group-Reference-Cited by-同舟云学术

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

Published:2014-11-28 Issue:3 Volume:62 Page:440-444
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Wagner Lars M.¹,Fouladi Maryam¹,Ahmed Atif²,Krailo Mark D.³,Weigel Brenda⁴,DuBois Steven G.⁵,Doyle L. Austin⁶,Chen Helen⁶,Blaney Susan M.⁷

Affiliation:

1. Division of Oncology; Cincinnati Children's Hospital Medical Center; Cincinnati Ohio

2. Department of Pathology; Mercy Children's Hospital; Kansas City Missouri

3. Department of Preventive Medicine; Keck School of Medicine; University of Southern California; Los Angeles California

4. Division of Pediatric Hematology/Oncology; University of Minnesota; Minneapolis Minneapolis

5. Division of Pediatric Hematology/Oncology; San Francisco School of Medicine; University of California; San Francisco California

6. Cancer Therapy Evaluation Program; National Cancer Institute; Bethesda Maryland

7. Division of Hematology/Oncology; Texas Children's Hospital; Baylor College of Medicine; Houston Texas

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference29 articles.

1. The biology behind mTOR inhibition in sarcoma;Wan;Oncologist,2007

2. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism;Wan;Oncogene,2007

3. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma;Kurmasheva;Cancer Res,2009

4. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program;Kolb;Pediatr Blood Cancer,2012

5. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models;Beltran;J Pharmacol Exp Ther,2011

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Oncology in Pediatric Cancer Surgery;Surgical Oncology Clinics of North America;2023-12

2. Bazedoxifene Suppresses the Growth of Osteosarcoma Cells by Inhibiting IL-6 and IL-11/GP130 Signaling Pathway;Journal of Pediatric Hematology/Oncology;2023-11-13

3. Cancer Stem Cells and Chemoresistance in Ewing Sarcoma;Current Stem Cell Research & Therapy;2023-10

4. Diagnosis and treatment of rhabdomyosarcomas;Oncology in Clinical Practice;2023-08-23

5. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma;Clinical Cancer Research;2023-07-03